BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing proprietary drug delivery technologies to develop and commercialize novel prescription, over-the-counter and supplement products that address large markets in dermatology and women’s health. The Company’s objective is to develop products that treat health or age-related conditions that are not presently being addressed or treated at all or are currently treated with drug therapies or drug delivery approaches that are sub-optimal. BioPharmX has developed a product portfolio using its drug delivery technologies, including delivery mechanisms for antibiotics, biologic materials, and molecular iodine.
The Company currently has one marketed product, a VI2OLET iodine dietary supplement, two clinical‑stage product candidates, BPX01 and BPX03 and one development‑stage product candidate, BPX02. VI2OLET is a molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches, and swelling. BPX03 is a prescription drug version of the molecular iodine tablet for the treatment of moderate to severe, periodic breast pain associated with FBC and cyclic mastalgia. BPX01 is a hydrophilic, topical antibiotic gel for the treatment of acne vulgaris and BPX02 is an injectable product utilizing biologic materials for aesthetic dermatology applications.
Revenue (Q1, 2019)
Gross profit (Q1, 2019)
Gross profit margin (Q1, 2019), %
EBIT (Q1, 2019)
Market capitalization (22-Jun-2018)
Closing share price (22-Jun-2018)